P. M. Webb and S. J. Jordan, Epidemiology of epithelial ovarian cancer, Best Pract Res Clin Obstet Gynaecol, vol.41, pp.3-14, 2017.

I. Vergote, C. G. Trope, and F. Amant, Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer, N Engl J Med, vol.363, pp.943-53, 2010.

D. S. Chen and I. Mellman, Oncology meets immunology: the cancer-immunity cycle, Immunity, vol.39, pp.1-10, 2013.

C. G. Clemente, M. C. Mihm, J. Bufalino, R. Zurrida, S. Collini et al., Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma, Cancer, vol.77, pp.1303-1313, 1996.

P. Salama, M. Phillips, and F. Grieu, Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer, J Clin Oncol, vol.27, pp.186-92, 2009.

K. Schumacher, W. Haensch, C. Roefzaad, and P. M. Schlag, Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas, Cancer Res, vol.61, pp.3932-3938, 2001.

A. N. Seo, H. J. Lee, and E. J. Kim, Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer, Br J Cancer, vol.109, pp.2705-2718, 2013.

R. Yamaguchi, M. Tanaka, and A. Yano, Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer, Hum Pathol, vol.43, pp.1688-94, 2012.

R. A. De-jong, N. Leffers, and H. M. Boezen, Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer, Gynecol Oncol, vol.114, pp.105-115, 2009.

E. Sato, S. H. Olson, and J. Ahn, Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer, Proc Natl Acad Sci U S A, vol.102, pp.18538-18581, 2005.

L. Zhang, J. R. Conejo-garcia, and D. Katsaros, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer, N Engl J Med, vol.348, pp.203-216, 2003.

S. Zhang, X. Ke, and S. Zeng, Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment, Cell Mol Immunol, vol.12, pp.580-91, 2015.

M. Tomsova, B. Melichar, I. Sedlakova, and I. Steiner, Prognostic significance of CD3+ tumorinfiltrating lymphocytes in ovarian carcinoma, Gynecol Oncol, vol.108, pp.415-435, 2008.

M. Stumpf, A. Hasenburg, and M. O. Riener, Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes, Br J Cancer, vol.101, pp.1513-1534, 2009.

V. Lavoue, A. Thedrez, and J. Leveque, Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer, Journal of translational medicine, vol.11, p.147, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00834422

B. Clarke, A. V. Tinker, and C. H. Lee, Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss, Mod Pathol, vol.22, pp.393-402, 2009.

K. N. Townsend, J. E. Spowart, and H. Huwait, Markers of T cell infiltration and function associate with favorable outcome in vascularized high-grade serous ovarian carcinoma, PLoS One, vol.8, p.82406, 2013.

M. P. Pinto, C. Balmaceda, and M. L. Bravo, Patient inflammatory status and CD4+/CD8+

, intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer, Gynecologic oncology, vol.151, pp.10-17, 2018.

T. J. Curiel, G. Coukos, and L. Zou, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, Nat Med, vol.10, pp.942-951, 2004.

C. Hermans, D. Anz, J. Engel, T. Kirchner, S. Endres et al., Analysis of FoxP3+ Tregulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers, PLoS One, vol.9, p.111757, 2014.

I. Kryczek, S. Wei, and G. Zhu, Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma, Cancer Res, vol.67, pp.8900-8905, 2007.

N. Leffers, M. J. Gooden, and R. A. De-jong, Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer, Cancer Immunol Immunother, vol.58, pp.449-59, 2009.

K. Milne, M. Kobel, and S. E. Kalloger, Systematic analysis of immune infiltrates in highgrade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors, PLoS One, vol.4, p.6412, 2009.

C. Denkert, G. Von-minckwitz, D. , and S. , Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy, Lancet Oncol, vol.19, pp.40-50, 2018.

T. Baert, I. Vergote, and A. Coosemans, Ovarian cancer and the immune system, Gynecol Oncol Rep, vol.19, pp.57-65, 2017.

T. B. Turner, D. J. Buchsbaum, J. M. Straughn, J. Randall, T. D. Arend et al., Ovarian cancer and the immune system -The role of targeted therapies, Gynecologic oncology, vol.142, pp.349-56, 2016.

Q. T. Huang, L. Zhou, and W. J. Zeng, Prognostic Significance of Neutrophil-to

, Lymphocyte Ratio in Ovarian Cancer: A Systematic Review and Meta-Analysis of Observational Studies, Cell Physiol Biochem, vol.41, pp.2411-2419, 2017.

Y. Wang, P. Liu, and Y. Xu, Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer, Cancer Chemother Pharmacol, vol.75, pp.255-62, 2015.

J. D. Wolchok, V. Chiarion-sileni, and R. Gonzalez, Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, The New England journal of medicine, vol.377, pp.1345-56, 2017.

E. A. Basak, S. Koolen, and D. P. Hurkmans, Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer, Eur J Cancer, vol.109, pp.12-20, 2019.

K. H. Kim, J. Cho, and B. M. Ku, The first-week proliferative response of peripheral blood PD-1(+)CD8(+) T cells predicts the response to anti-PD-1 therapy in solid tumors, Clin Cancer Res, 2019.

N. Riaz, J. J. Havel, and V. Makarov, Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab, Cell, vol.171, pp.934-983, 2017.

J. Hamanishi, M. Mandai, and T. Ikeda, Safety and Antitumor Activity of Anti-PD, issue.1

N. Antibody, Patients With Platinum-Resistant Ovarian Cancer, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.33, pp.4015-4037, 2015.

U. A. Matulonis, R. Shapira-frommer, and A. Santin, Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study. (Abstract), Journal of Clinical Oncology, 2018.

A. Varga, S. A. Piha-paul, and P. A. Ott, Pembrolizumab in patients (pts) with PD-L1-positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028. (Abstract), Journal of Clinical Oncology, 2017.

A. Strasser, P. J. Jost, and S. Nagata, The many roles of FAS receptor signaling in the immune system, Immunity, vol.30, pp.180-92, 2009.

N. Holler, A. Tardivel, and M. Kovacsovics-bankowski, Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex, Mol Cell Biol, vol.23, pp.1428-1468, 2003.

F. C. Kischkel, S. Hellbardt, and I. Behrmann, Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor, The EMBO journal, vol.14, pp.5579-88, 1995.

T. S. Kokkonen, M. T. Augustin, J. Kokkonen, R. Karttunen, and T. J. Karttunen, Serum and tissue CD23, IL-15, and FasL in cow's-milk protein-sensitive enteropathy and in coeliac disease, Journal of pediatric gastroenterology and nutrition, vol.54, pp.525-556, 2012.

T. S. Kokkonen and T. J. Karttunen, Endothelial Fas-Ligand in Inflammatory Bowel Diseases and in Acute Appendicitis, J Histochem Cytochem, vol.63, pp.931-973, 2015.

G. T. Motz, S. P. Santoro, and L. P. Wang, Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors, Nature medicine, vol.20, pp.607-622, 2014.

S. Tauzin, B. Chaigne-delalande, and E. Selva, Poissonnier A, Legembre P. Boyden Chamber Assay to Study of Cell Migration Induced by Metalloprotease Cleaved-CD95L, Methods Mol Biol, vol.9, pp.117-140, 2011.

J. Prat and O. Fcog, Staging classification for cancer of the ovary, fallopian tube, and peritoneum, Int J Gynaecol Obstet, vol.124, pp.1-5, 2014.

S. Hendry, R. Salgado, and T. Gevaert, Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research, Adv Anat Pathol, vol.24, pp.235-51, 2017.

C. Contal, O. Quigley, J. Q. , and J. , An application of changepoint methods in studying the effect of age on survival in breast cancer, Computational Statistics & Data Analysis, vol.30, pp.252-70, 1999.

M. Roy, J. Connor, A. Al-niaimi, S. L. Rose, and A. Mahajan, Aldehyde dehydrogenase 1

, ALDH1A1) expression by immunohistochemistry is associated with chemo-refractoriness in patients with high-grade ovarian serous carcinoma, Hum Pathol, 2017.

M. Luyckx, E. Leblanc, and T. Filleron, Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, vol.22, pp.1337-1380, 2012.

R. A. Cowan, A. Eriksson, and S. M. Jaber, A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer, Gynecol Oncol, vol.145, pp.230-235, 2017.

A. Kreso and J. E. Dick, Evolution of the cancer stem cell model, Cell Stem Cell, vol.14, pp.275-91, 2014.

T. Oskarsson, E. Batlle, and J. Massague, Metastatic stem cells: sources, niches, and vital pathways, Cell Stem Cell, vol.14, pp.306-327, 2014.

A. Poissonnier, D. Sanseau, L. Gallo, and M. , CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice, Immunity, vol.45, pp.209-232, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02378067

H. Vira, V. Pradhan, and V. Umare, Role of MMP-7 in the pathogenesis of systemic lupus erythematosus (SLE), Lupus, vol.26, pp.937-980, 2017.

, Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma, Nature, vol.474, pp.609-624, 2011.

A. Barbarin, E. Cayssials, and F. Jacomet, Phenotype of NK-Like CD8(+) T Cells with Innate Features in Humans and Their Relevance in Cancer Diseases, Front Immunol, vol.8, p.316, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01518119

J. C. Barnett, S. M. Bean, and R. S. Whitaker, Ovarian cancer tumor infiltrating Tregulatory (T(reg)) cells are associated with a metastatic phenotype, Gynecol Oncol, vol.116, pp.556-62, 2010.

A. R. Hagemann, I. S. Hagemann, and M. Cadungog, Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma, Cancer Biol Ther, vol.12, pp.367-77, 2011.

V. Schiavon, S. Duchez, and M. Branchtein, Microenvironment tailors nTreg structure and function, Proc Natl Acad Sci, vol.116, pp.6298-307, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02392153

M. Malleter, S. Tauzin, and A. Bessede, CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer, Cancer research, vol.73, pp.6711-6732, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00873634